Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsLiabilities and Shareholders EquityNon-Current AssetsOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Whitehawk Therapeutics (WHWK) Non-Current Assets (2018 - 2025)

Whitehawk Therapeutics (WHWK) has disclosed Non-Current Assets for 8 consecutive years, with $2.0 million as the latest value for Q3 2025.

  • On a quarterly basis, Non-Current Assets fell 76.37% to $2.0 million in Q3 2025 year-over-year; TTM through Sep 2025 was $14.6 million, a 56.35% decrease, with the full-year FY2024 number at $9.0 million, up 15.25% from a year prior.
  • Non-Current Assets was $2.0 million for Q3 2025 at Whitehawk Therapeutics, down from $2.2 million in the prior quarter.
  • In the past five years, Non-Current Assets ranged from a high of $9.0 million in Q4 2024 to a low of $29452.0 in Q2 2021.
  • A 5-year average of $5.2 million and a median of $6.3 million in 2023 define the central range for Non-Current Assets.
  • Peak YoY movement for Non-Current Assets: tumbled 89.52% in 2021, then soared 14503.42% in 2022.
  • Whitehawk Therapeutics' Non-Current Assets stood at $6.6 million in 2021, then crashed by 36.61% to $4.2 million in 2022, then surged by 86.24% to $7.8 million in 2023, then rose by 15.25% to $9.0 million in 2024, then crashed by 78.07% to $2.0 million in 2025.
  • Per Business Quant, the three most recent readings for WHWK's Non-Current Assets are $2.0 million (Q3 2025), $2.2 million (Q2 2025), and $1.4 million (Q1 2025).